Good MorningThe equities market got another shot of anti-viral medication on Thursday when Jerome Powell announced major changes in how the Federal Reserve views inflation. Instead of taking inflation at face value, the committee will use an average-inflation approach in an effort to help sustain economic growth. Under the new policy, inflation could run well above the 2.0% target before any policy action or business-stifling rate increases would be taken.
The Fed changes are intended to sustain and accelerate economic growth in the U.S. and the markets responded favorably. The Dow Jones Industrial Average led the days advance with a gain near 1.0% to set a new high for 2020. The S&P 500 and NASDAQ Composite posted smaller advances but both set new highs as well. Investors should expect to see more new highs so long as the data remains favorable.
Featured: New stock hack lets you in before the morning open (Investpub (Wealthpress campaigns)) 
|
Markets | | |
It’s always good to find a bargain. And it’s especially good to make a dollar stretch further in uncertain economic times like these. That formula is working for Ollie’s Bargain Outlet (NASDAQ:OLLI). And investors will find out how well the discount chain is doing when they repor... Read the Full Story |
|
From Our PartnersForget cryptos, pot stocks, and other "shiny object" investments. Instead, you could collect an average of $185 every day of the year with this "boring" trade strategy Forbes magazine says is "like finding money in the street." | | For full details, click here. |
|
Markets | | | JD.com Inc (NASDAQ:JD) is the 2nd largest e-commerce company in China and looks like a strong buy at this time. The company reported strong earnings recently and is hitting new all-time highs as a result. Read the Full Story |
|
Markets | | | One sector that has been a big winner throughout the novel coronavirus pandemic has been the discount retail sector. The discount retail sector is a $95 billion sector. Names like Walmart (NYSE:WMT) and Target (NYSE:TGT) are among the first to come to mind when consumers think low prices. But they a... Read the Full Story |
|
From Our PartnersInvestors could collect 24-hour windfalls right under the noses of ordinary Americans.
But a Florida man in his 30's just "hacked" an institutional level scanner.
There are reports of massive gains like the 1,360% just earned on KHC.
YOU could tap into these 24-hour windfalls and earn up to 843% per trade.
Lance says there's even ONE specific trade on his radar now. | | Click HERE to see the Specific Trade |
|
Markets | | |
The superhero streaming wars is heating up between Walt Disney’s (NYSE: DIS) Marvel Cinematic Universe (MCU) versus AT&T’s Warnermedia’s (NYSE: T) DC Extended Universe (DCEU). For those not familiar with superhero universes, Marvel Studios broke the mold along with all box of... Read the Full Story |
|
Markets | | |
It might be hard to reconcile how a large number of analysts are expecting a stock's price to fall, substantially, yet at the same time be worth buying, but sometimes, that's exactly the case. That's just what's going on with Qorvo (NASDAQ:QRVO), which is turning in big expectations in pretty much... Read the Full Story |
|
From Our PartnersMost of the world's richest investors totally ignore company fundamentals like P/E ratios. Those metrics have NOTHING to do with what makes stocks rise or fall. One indicator is far more accurate -- but less than 1 in 1,000 investors have ever heard of it. | | This is how wealth is really made in the stock market today. |
|
The Early Bird Stock Of The Day Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. | | View Today's Stock Pick |
|
